Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Triiodothyronine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Triiodothyronine. Displaying page 1 of 1.
    EudraCT Number: 2020-001623-13 Sponsor Protocol Number: T3inj-02/Thy-Support Start Date*: 2020-05-20
    Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
    Full Title: Triiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study)
    Medical condition: ICU patients diagnosed with pulmonary infection due to COVID-19 and require mechanical respiratory support or ECMO
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001541-18 Sponsor Protocol Number: T3RIS22007 Start Date*: 2007-10-08
    Sponsor Name:Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine
    Full Title: Triiodothyronine as an adjunct in treatment of acute schizophrenia
    Medical condition: Acute Schizoprenia episode
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001065 Acute schizophrenia episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000631-40 Sponsor Protocol Number: T3inj-01 Start Date*: 2016-04-04
    Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
    Full Title: Triiodothyronine for repair of left ventricular dysfunction and Remodeling in STEMI Patients
    Medical condition: Patients with anterior or anterolateral STEMI subjected to primary PCI.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064346 STEMI LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-001540-45 Sponsor Protocol Number: EST312007 Start Date*: 2007-06-14
    Sponsor Name:Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine
    Full Title: Triiodothyronine as an adjunct to accelerate the antidepressant effects of the selective serotonin reuptake inhibitor (SSRI) escitalopram
    Medical condition: Depressive episode
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012402 Depressive episode LLT
    Population Age: Adults Gender: Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001681-25 Sponsor Protocol Number: 23681 Start Date*: 2015-07-15
    Sponsor Name:Merck KGaA
    Full Title: An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Ex...
    Medical condition: Small for Gestational Age
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-010869-23 Sponsor Protocol Number: THIRST 02/2009 Start Date*: 2009-06-22
    Sponsor Name:OSPEDALE G.PASQUINUCCI-FONDAZIONE TOSCANA GABRIELE MONASTERIO/CNR
    Full Title: Acute and long term effects of thyroid hormone replacement therapy in patients with ST-Elevation Myocardial Infarction (STEMI) and borderline/reduced triiodothyronine levels.
    Medical condition: All patients enrolled in the study should be in good clinical conditions, being ST-elevation myocardial infarction the main pathology,, without evidence of clinical/hemodynamic instability. All pat...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007541 SOC
    9.1 10011085 HLT
    9.1 10028596 PT
    9.1 10000891 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001158-33 Sponsor Protocol Number: OZR-2016-34 Start Date*: 2017-07-20
    Sponsor Name:The Rotterdam Eye Hospital
    Full Title: A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of Graves’ Orbitopathy with reduced systemic steroid exposure
    Medical condition: Graves' Orbitopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-001478-78 Sponsor Protocol Number: MCT8-2021-3 Start Date*: 2023-03-31
    Sponsor Name:Rare Thyroid Therapeutics International AB
    Full Title: Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double blind, Randomized, Placebo controlled Study
    Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency
    Disease:
    Population Age: Children, Under 18, Adults Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001695-34 Sponsor Protocol Number: LUM-201-04 Start Date*: 2022-09-08
    Sponsor Name:Lumos Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Months of Daily rhGH Treatment in Children with Idiopathic Growth Hormone Deficiency who have Previou...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002713-58 Sponsor Protocol Number: HZNP-TEP-302 Start Date*: 2018-08-13
    Sponsor Name:Horizon Therapeutics USA, Inc.
    Full Title: Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN.001) Treatment in Subjects with Thyroid Eye Disease
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004594-32 Sponsor Protocol Number: IO102-IO103-013/MK3475-D18 Start Date*: 2022-02-16
    Sponsor Name:IO Biotech ApS
    Full Title: An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (adv...
    Medical condition: Patients with previously untreated, unresectable or metastatic (advanced) melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Prematurely Ended) BE (Trial now transitioned) HU (Trial now transitioned) PT (Completed) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000113-31 Sponsor Protocol Number: TED01RV Start Date*: 2014-07-14
    Sponsor Name:River Vision Development Corporation
    Full Title: A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks...
    Medical condition: Thyroid-Associated Ophthalmopathy / Graves' Ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000641-41 Sponsor Protocol Number: 2021-000641-41 Start Date*: 2022-01-07
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: PROSPECTIVE COMPARISON OF SIROLIMUS AGAINST CORTICOSTEROIDS IN TREATMENT OF PATIENTS WITH ACTIVE THYROID EYE DISEASE
    Medical condition: Thyroid Eye Disease (TED) in patients with Graves' Diease.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002389-62 Sponsor Protocol Number: 8-55-52030-309 Start Date*: 2015-03-02
    Sponsor Name:Ipsen Group
    Full Title: Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of lanreotide PRF in subjects wi...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) CZ (Completed) LT (Completed) ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002763-18 Sponsor Protocol Number: HZNP-TEP-301 Start Date*: 2018-02-22
    Sponsor Name:Horizon Therapeutics USA, Inc.
    Full Title: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease (OPTIC Trial)
    Medical condition: Active Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004676-35 Sponsor Protocol Number: RVT-1401-2001 Start Date*: 2019-10-23
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: ASCEND GO2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Graves’ Ophthalmopathy
    Medical condition: Graves´Ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006794-37 Sponsor Protocol Number: VRDN-001-101 Start Date*: 2022-05-20
    Sponsor Name:Viridian Therapeutics, Inc.
    Full Title: A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and sub...
    Medical condition: Thyroid eye disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004853 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005999-36 Sponsor Protocol Number: HZNP-TEP-402 Start Date*: 2022-05-24
    Sponsor Name:Horizon Therapeutics U.S.A., Inc.
    Full Title: A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durat...
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005092-33 Sponsor Protocol Number: M10-221 Start Date*: 2008-06-10
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: The PRIMO II Study: Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5
    Medical condition: Stage 5 Chronic Kidney Disease (CKD) in subjects receiving hemodialysis who have left ventricular hypertrophy (LVH).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    9.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Prematurely Ended) CZ (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001689-34 Sponsor Protocol Number: M10-030 Start Date*: 2008-04-24
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: The PRIMO Study: Paricalcitol Capsules benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 3B/4. Estudio Primo: Beneficios de Paricalcitol cápsulas sob...
    Medical condition: Stage 3B/4 chronic kidney disease (CKD) in subjects who have left ventricular hypertrophy (LVH). Insuficiencia renal crónica en estadío 3B/4 en sujetos con hipertrofia ventricular izquierda.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    9.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) GB (Completed) IT (Completed) DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:38:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA